TITLE:
The Role of Vitamin D3 Therapy in Pediatric Bronchiectasis Severity (CF versus Non-CF Patients)
AUTHORS:
Heba A. Ali, Thrwat E. Deraz, Dina A. Mohamed, Menna Z. Mahmoud
KEYWORDS:
Cystic Fibrosis, Non-CF Bronchiectasis, Vitamin D3 Supplementation, Exacerbation, FEV1
JOURNAL NAME:
Open Journal of Pediatrics,
Vol.10 No.3,
September
25,
2020
ABSTRACT: Objective: To determine and compare the effect of vitamin D3 supplementation on
modifying the disease severity in cystic fibrosis (CF) and non-CF bronchiectasis
pediatric patients. Methods: A randomized clinical trial evaluating the role of oral vitamin D3
supplementation for six months, was performed in forty patients with CF and non-CF bronchiectasis under
the age of 18 years with vitamin D deficiency or insufficiency. The primary
outcome was to reach the sufficient Vitamin D level, the secondary outcome was
to reevaluate bronchiectasis severity by following up the frequency, severity
of pulmonary exacerbations and lung function after vitamin D3 supplementation. Results: Forty patients completed the trial. The percentage of improvement of
vitamin D level after vitamin D3 supplementation for six months was
significantly higher in CF (88.3%) than non-CF bronchiectasis patients (59.82%) (P = 0.03). Additionally, moderate to
severe pulmonary exacerbations significantly decreased by more than 60%, 45% (P = 0.001, 0.005) and frequent exacerbations decreased by 15%,
10% (P = 0.327, 0.490), while the
forced expiratory volume in 1 (FEV1) significantly increased by 17% and 15% in
non CF bronchiectasis and CF patients respectively (p 0.001). Conclusions: Vitamin D3 therapy was effective in decreasing the frequency
and severity of pulmonary exacerbations and preserving lung function. Thereby,
improving the disease severity even more in non-CF bronchiectasis than CF patients.